Investor

Investor Relations

Aligning business development with innovation adoption timing is crucial in the emerging psychedelic industry. 

Why invest now?

$1.2M in training revenue (2023)

8 corporate and 24 member clinics planned through 2024-2025

Phase 2 (2024), Phase 3 (2025), and monetizable drug protocol IP (2026)

Lykos, Compass, Cybin, Usona, MindMed and Algermon all progressing in their clinical trials and regulatory approvals for MDMA, psilocybin, LSD and DMT.

Alberta has rolled out licensing and accreditation regulations, rest of Canada to follow. Alberta Blue Cross initiated PaT coverage effective March 2024

Send us a message